Publications by authors named "Crizia Colombo"
Background: Bronchiectasis is a chronic respiratory condition characterised by airway and systemic inflammation with prevalence increasing with age. Given the median age of the patients, it is common to observe the presence of comorbidities, particularly cardiovascular diseases, which have been linked to adverse clinical outcomes. To investigate the pooled estimates of the association between bronchiectasis and coronary heart disease or stroke within this population, we conducted a systematic review and meta-analysis of the available scientific evidence.
View Article and Find Full Text PDFAims: The coronavirus disease-19 (COVID-19) outbreak has been recently associated with lower hospitalization rates for acute coronary syndromes. Aim of the study was to investigate whether a similar behaviour is observed in admissions for urgent pacemaker implant.
Methods: This retrospective study included 1315 patients from 18 hospitals in Northern Italy with a high number of COVID-19 cases.
In cardiac resynchronization therapy (CRT) implantation procedures, contrast-induced nephropathy risk and ionizing radiation exposure can be eliminated using electroanatomical mapping system (EAMS). Under EAMS guidance, it is possible to place the left ventricular catheter in the branch of the coronary sinus that presents the latest activation. The use of EAMS allows for both arrhythmic ablation and CRT implantation to be obtained in a single, "zero fluoroscopy" procedure.
View Article and Find Full Text PDFArticle Synopsis
- The study analyzed the effectiveness of hydroxychloroquine (HCQ) in treating COVID-19 by observing 4,396 patients hospitalized in Italy from February to May 2020, revealing mixed results from previous research.
- Two patient clusters were identified: a younger, healthier group at lower risk of death and an older, sicker group at higher risk, highlighting differing impacts of HCQ on these populations.
- HCQ appeared to significantly reduce mortality risk in the lower risk cluster, suggesting that it may be more beneficial for patients with fewer comorbidities, potentially clarifying debates around its efficacy in COVID-19 treatment.
Protease inhibitors have been considered as possible therapeutic agents for COVID-19 patients. To describe the association between lopinavir/ritonavir (LPV/r) or darunavir/cobicistat (DRV/c) use and in-hospital mortality in COVID-19 patients. Multicenter observational study of COVID-19 patients admitted in 33 Italian hospitals.
View Article and Find Full Text PDFArticle Synopsis
- The study focuses on understanding the varied prognosis of COVID-19 by identifying clinical and laboratory indicators that can predict poor outcomes in hospitalized patients.
- Researchers analyzed data from 664 COVID-19 patients in Northern Italy, discovering that factors like red cell distribution width (RDW), neutrophil-to-lymphocyte (NL) ratio, and platelet count are significant predictors of in-hospital mortality.
- The results suggest that using simple blood tests could help in classifying the severity of COVID-19, ultimately guiding treatment and monitoring strategies for better patient management.
A pro-thrombotic milieu and a higher risk of thrombotic events were observed in patients with CoronaVirus disease-19 (COVID-19). Accordingly, recent data suggested a beneficial role of low molecular weight heparin (LMWH), but the optimal dosage of this treatment is unknown. We evaluated the association between prophylactic vs.
View Article and Find Full Text PDFArticle Synopsis
- - The study investigated whether administering heparin in hospitals improves survival rates among COVID-19 patients, due to a linked hypercoagulable condition that can worsen the disease.
- - An analysis of 2,574 patients across Italy showed that 70.1% received heparin, leading to significantly lower death rates (7.4 vs. 14.0 per 1,000 person-days) among those treated with heparin.
- - The findings suggest that heparin is associated with a 40% reduction in death risk, especially for critically ill patients, indicating its potential benefit, although further randomized clinical trials are necessary for definitive guidance.
Clinical features and natural history of coronavirus disease 2019 (COVID-19) differ widely among different countries and during different phases of the pandemia. Here, we aimed to evaluate the case fatality rate (CFR) and to identify predictors of mortality in a cohort of COVID-19 patients admitted to three hospitals of Northern Italy between March 1 and April 28, 2020. All these patients had a confirmed diagnosis of SARS-CoV-2 infection by molecular methods.
View Article and Find Full Text PDF